Navigation Links
New drug combination therapy developed to treat leukemia
Date:4/17/2013

A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival proteins. The effectiveness of the therapy lies in its ability to target a pro-survival cell signaling pathway known as PI3K/AKT/mTOR, upon which the leukemia cells have become dependent.

In the study, published in the journal Cancer Research, researchers combined the drug ABT-737 with another agent BEZ235. ABT-737 targets proteins known as B-cell lymphoma 2 (Bcl-2) and Bcl-xL, which prevent apoptosis, a form of cell suicide, in cancer cells. BEZ235 directly inhibits the PI3K/AKT/mTOR pathway, and as a result, reduces the expression of another anti-apoptotic protein known as Mcl-1, which is not targeted by ABT-737. Among their many functions, signaling pathways regulate biological processes required for cellular survival. The PI3K/AKT/mTOR pathway helps keep apoptosis in check, in part, by controlling the production of Mcl-1. However, the pathway can become dysregulated in cancer, and in so doing, contribute to uncontrolled tumor growth and resistance to conventional cancer therapies. It is activated in 50 to 80 percent of patients with acute myelogenous leukemia (AML), and in some, but not all cases, is associated with genetic mutations. Significantly, disabling both anti-apoptotic proteins, Bcl-2 and Bcl-xL, in conjunction with Mcl-1, caused profound cell death of leukemia cells in the test tube as well as in animal models of AML.

"This study builds on many years of work in our laboratory investigating the mechanisms that regulate apoptosis in human leukemia cells. To the best of our knowledge, it is the first to raise the possibility that activation of the P13K/AKT/mTOR pathway, rather than genetic mutations within the pathway, may represent the best predictor of leukemia cell responses to these targete
'/>"/>

Contact: Alaina Farrish
akfarrish@vcu.edu
804-628-4578
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Immunotherapy for elderly cancer patients finds new promise in drug combination
2. Combination of 2 drugs reverses liver tumors
3. Cancer vaccine combination therapy shows survival benefit in breast cancer
4. Discovery suggests new combination therapy strategy for basal-like breast cancers
5. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
6. BUSM in vitro study identifies potential combination therapy for breast cancer
7. DNDi and Cipla to develop 4-in-1 pediatric antiretroviral drug combination
8. Combination peptide therapies might offer more effective, less toxic cancer treatment
9. Drug combination against NRAS-mutant melanoma discovered
10. Combination treatment may improve survival of breast cancer patients with brain metastases
11. Scientists test 5,000 combinations of 100 existing cancer drugs to find more effective treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Miami, FL (PRWEB) July 31, 2014 ... (LMS) which continues to help healthcare agencies to ... help companies and agencies meet their accreditation ... with competency based training. , Healthcare administrators ... a few clicks of the mouse. Courses can ...
(Date:7/31/2014)... July 31, 2014 Current residents at ... treatment program in Flagstaff, AZ, learn to kayak safely ... equipment and paddle strokes in preparation for next week's ... "I think that [the kayaking course] teaches [residents] to ... struggle with in their early part of their sobriety," ...
(Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 Located ... the street from Macy’s, The Rothenberg Law Firm LLP has ... 450 Seventh Avenue. , The Rothenberg Law Firm has been ... move has been spurred by growth in the firm’s continued ... York. The firm’s New York office has a team of ...
(Date:7/31/2014)... Elk Grove Village, IL (PRWEB) July 31, 2014 ... hearing wellness solutions, today announced a new sponsorship ... events. Front and center are Etymotic’s hearing protection ... maintain high-fidelity while protecting against the harmful effects ... to kick off the sponsorship at the Drum ...
(Date:7/31/2014)... July 31, 2014 According to a ... Journal , Endo International, one of several manufacturing companies ... of transvaginal claims for $830 million (in re: American ... (MDL No. 2325). Melinda Helbock, Founder of The Law ... with the settlement and is pleased to see litigation ...
Breaking Medicine News(10 mins):Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Back2Basics Substance Abuse Residents Take Kayaking Class for the First Time 2Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2Health News:San Diego Product Liability Firm Provides Commentary on the Latest Developments in Transvaginal Mesh Litigation 2
... Lack of adequate sleep can lead to increased injuries ... in Public Health Nursing shows that the average number of ... children who dont get enough sleep each day as described ... percent of all children in the United States sustain injuries ...
... of 100 patients suffering from a ruptured brain aneurysm ... more effective than bare platinum coils at preventing aneurysms ... from the Neuroscience Institute at the University of Cincinnati ... evaluated the risk of intracranial aneurysm recurrence after endovascular ...
... , , THURSDAY, Feb. 21 (HealthDay News) -- Nodding off ... that matter, may raise your risk of stroke, a ... report a potentially important association between daytime dozing, which ... V. Pacia, director of neurology at Lenox Hill Hospital ...
... happens, CDC says , , THURSDAY, Feb. 21 (HealthDay News) -- ... of a heart attack, and the percentage who know what to ... could be, a survey by the U.S. Centers for Disease Control ... CDC,s Morbidity and Mortality Weekly Report , are part ...
... Sandata Technologies,Inc., a leading IT services ... social,services community, today announced it has acquired ... Minnesota. TeleTimecard,is an Application Service Provider (ASP) ... offsite workers and has been a long-standing ...
... American Imaging Management,(AIM), an operating subsidiary of ... radiology benefit management and technology company with health,plan ... an,enhanced Patient Safety Program to increase awareness of ... computed tomography,(CT) scans and positron emission tomography (PET) ...
Cached Medicine News:Health News:UC study: New devices less effective in thwarting brain aneurysm recurrence 2Health News:Daytime Dozing Might Raise Stroke Risk 2Health News:Awareness of Heart Attack Signs Lags in U.S. 2Health News:Awareness of Heart Attack Signs Lags in U.S. 3Health News:Sandata Technologies, Inc. Adds TeleTimecard to its Service Offering 2Health News:Sandata Technologies, Inc. Adds TeleTimecard to its Service Offering 3Health News:American Imaging Management Launches Patient Safety Program to Increase Awareness of Radiation Dose Associated with Advanced Imaging Procedures 2Health News:American Imaging Management Launches Patient Safety Program to Increase Awareness of Radiation Dose Associated with Advanced Imaging Procedures 3
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
(Date:7/31/2014)... 31, 2014 Xencor Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "In the second quarter, ... Society 2014 International Conference (ATS) demonstrating three novel ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, Inc. ... update on its pipeline and new product development ... to initiate a Phase 2a study of AZ-002 ... for the management of patients with acute repetitive ... Staccato -based product candidates for development - AZ-008 ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... patients,have complained for years about the mental fog ... Virginia University, researchers have discovered,that injections of N-acetyl ... that breast cancer chemotherapy drugs sometimes induce., ... September issue of the,journal Metabolic Brain Disease, rats ...
... W.Va., Sept. 5 A team of,researchers at ... from,India and Pakistan take on the habits of ... among male immigrants and breast cancer,among females., ... many reasons, but,environmental factors and lifestyle play a ...
Cached Medicine Technology:Study Suggests a Possible Way to Offset Chemobrain Memory Loss 2Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks 2
... The Leica RM2235 is a robust ... of primarily biological specimens embedded in ... backlash-free precision micrometer feed system ensures ... even when sectioning harder tissues. The ...
... biomedical and industrial applications, the Leica SM2400 ... of applications in all laboratories where paraffin ... sectioned. Its sturdy construction lends it qualities ... features of the system, such as a ...
... Automatic microtome with vibrating blade for fixed and ... as for non-biological specimen in material science ... of blade amplitude between 0,1 and 1,2 mm ... parameters can be set independently from each other. ...
... EC 350 consists of two modular units. ... surface and reaches a temperature of -15C. ... reservoir, heated dispenser nozzle, heated work surface, ... separate heated compartments for molds and cassettes. ...
Medicine Products: